Blood Clot Prevention │Treatment

Blood Clot Prevention

While haemostasis is necessary for survival, the pathological formation of a blood clot, or thrombosis, poses significant health risks. Venous thromboembolism (VTE) is one of the most frequent serious complications following major orthopaedic surgery, such as elective hip or knee replacement surgery.6

Xarelto® is the first oral once-daily direct Factor Xa inhibitor (approved in the European Union for the prevention of VTE in adult patients undergoing elective hip or knee replacement surgery) with uniquely targeted action in preventing blood clots.

Blood Clot Treatment

Activated Factor X (Factor Xa) is the central point of amplification in the coagulation cascade, as 1 molecule catalyses the formation of approximately 1,000 thrombin molecules.

Xarelto® precisely targets this pivotal point in the coagulation cascade, which is a chain of biochemical reactions essential to the formation of blood clots.25, 26, 27

See also: Factor Xa


  • 6 - Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
  • 25 - Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.
  • 26 - Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.
  • 27 - Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60.